Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial

Autor: Clemmons, Amber B., Orr, Julianne, Andrick, Benjamin, Gandhi, Arpita, Sportes, Claude, DeRemer, David
Zdroj: In Biology of Blood and Marrow Transplantation October 2018 24(10):2065-2071
Databáze: ScienceDirect
Externí odkaz: